Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. HOOD
10. MSTR

Go back to Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
(NASDAQ: LTRN) Delayed: 3.92 +0.13 (3.43%)
Previous Close $3.79    52 Week High $ 
Open $3.84    52 Week Low $ 
Day High $4.10    P/E N/A 
Day Low $3.77    EPS $ 
Volume 87,378